NCT01710852 (ASET) is a Phase 2 clinical trial of ISIS CRP Rx in Paroxysmal Atrial Fibrillation, sponsored by Ionis Pharmaceuticals, Inc..

Who is sponsoring NCT01710852?

NCT01710852 is sponsored by Ionis Pharmaceuticals, Inc..

What drugs are being tested in NCT01710852?

Interventions in NCT01710852: ISIS CRP Rx, Placebo.

What condition does NCT01710852 study?

NCT01710852 studies Paroxysmal Atrial Fibrillation.

Is NCT01710852 still recruiting?

NCT01710852 is currently completed. Last updated 24 August 2015.

Last reviewed 2015-08-24 · How we verify

NCT01710852: ASET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2 Study to Assess the Antiarrhythmic and Symptomatic Effect of the Second Generation Antisense Oligonucleotide ISIS 329993 Targeting CRP in Patients With Paroxysmal Atrial Fibrillation

Completed Phase 2 Last updated 24 August 2015

What this trial tests

Phase 2 trial testing ISIS CRP Rx in Paroxysmal Atrial Fibrillation in 7 participants. Completed in 1 April 2014.

Timeline

1 October 2012

Primary endpoint
1 April 2014

1 April 2014

Quick facts

Lead sponsor	Ionis Pharmaceuticals, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	7
Start date	1 October 2012
Primary completion	1 April 2014
Estimated completion	1 April 2014
Sites	1 location across United Kingdom

Drugs / interventions tested

ISIS CRP Rx — full drug profile →
Placebo

Conditions studied

Paroxysmal Atrial Fibrillation — all drugs for Paroxysmal Atrial Fibrillation →

Sponsor

Ionis Pharmaceuticals, Inc. — full company profile →

Who can join

18 and older, any sex, with Paroxysmal Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

AF burden reduction
Time frame: 113 Days
Burden measured as percentage of time spent in AF as derived from continuous pacemaker monitoring

Sponsor's own description

The purpose of this study is to evaluate whether treatment with ISIS CRP Rx can reduce AF (Atrial Fibrillation) burden (percentage of time spent in AF) in subjects with paroxysmal AF

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

RNA therapeutics: RNAi and antisense mechanisms and clinical applications.
Chery J. · · 2016 · cited 159× · PMID 27570789 · DOI 10.14304/surya.jpr.v4n7.5
Therapeutic nucleic acids: current clinical status.
Sridharan K, Gogtay NJ. · · 2016 · cited 153× · PMID 27111518 · DOI 10.1111/bcp.12987
A novel phosphocholine-mimetic inhibits a pro-inflammatory conformational change in C-reactive protein.
Zeller J, Cheung Tung Shing KS, Nero TL, McFadyen JD, et al · · 2023 · cited 43× · PMID 36468184 · DOI 10.15252/emmm.202216236
RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases.
Bejar N, Tat TT, Kiss DL. · · 2022 · cited 32× · PMID 35364795 · DOI 10.1007/s11883-022-01007-9
mRNA therapy for myocardial infarction: A review of targets and delivery vehicles.
Wang X, Wu DH, Senyo SE. · · 2022 · cited 11× · PMID 36507276 · DOI 10.3389/fbioe.2022.1037051

Verify or expand the search:

Other recruiting trials for Paroxysmal Atrial Fibrillation

Currently open trials in the same condition.

NCT07535268 — REPRESENT-PF Registry · recruiting
NCT07344961 — Determinates of Atrial Tracking and Prevalence of Atrial Fibrillation in the Micra AV2 (DANCE AFIB) · recruiting
NCT07281898 — Burst Stimulation for Paroxysmal Atrial Fibrillation · NA · recruiting
NCT07116525 — A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter · NA · recruiting
NCT06765356 — Pragmatic Evaluation of a Pentaspline Pulsed Field Ablation System to Treat Atrial Fibrillation and Related Arrhythmias · Phase 4 · active not recruiting

Other Ionis Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT06673069 — Hero: A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) and Pharmacodynamics (PD) of ION269 in Par · Phase 1 · terminated
NCT06014541 — Observational Study to Characterize Biomarkers and Disease Progression in Participants With Methyl CpG Binding Protein 2 · terminated
NCT05610280 — A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, · Phase 3 · completed
NCT05579860 — A Study Comparing Two Subcutaneous Formulations: Vial and Autoinjector (AI) With Olezarsen, at Two Dose Levels, in Healt · Phase 1 · completed
NCT05552326 — A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01710852 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ionis Pharmaceuticals, Inc.
Last refreshed: 24 August 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01710852.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing